In a report released today, Leland Gershell from Oppenheimer maintained a Hold rating on Alnylam Pharma (ALNY – Research Report). The company’s shares closed yesterday at $150.31.
According to TipRanks, Gershell is a 3-star analyst with an average return of 2.2% and a 35.67% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Catalyst Pharma, Crinetics Pharmaceuticals, and Alnylam Pharma.
In addition to Oppenheimer, Alnylam Pharma also received a Hold from Leerink Partners’s Mani Foroohar in a report issued on April 25. However, yesterday, Chardan Capital reiterated a Buy rating on Alnylam Pharma (NASDAQ: ALNY).
The company has a one-year high of $218.88 and a one-year low of $141.98. Currently, Alnylam Pharma has an average volume of 837.5K.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharma (ALNY) Company Description:
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
